Scientists are developing the world’s first lateral flow test to detect brain tumors.
The lateral flow test is a method used to identify biomarkers in urine, saliva or blood samples for diagnostic purposes.
This type of test was used during the Covid-19 outbreak and attracted attention for its ability to be used at home.
According to the British newspaper The Telegraph, scientists said the new test will target aggressive and recurrent tumors that currently kill about 200,000 people a year worldwide.
It was noted that the test will only work by taking blood from the finger, reducing the need for MRI scans and significantly reducing the burden on health systems as an effective and more cost-effective alternative.
Prof. Philip Wilson, who led the team of scientists from Nottingham Trent University, made the following statement about the new test:
“As well as detecting tumors, this technology will enable regular monitoring of tumors previously detected by MRI at home in an easy-to-use and cost-effective way. Unfortunately, recurrence of brain tumors is common and a major problem. Some of these tumors come back very quickly. So regular home tests are a game changer in this regard.”
Wilson noted that what sets the lateral flow test apart is its ability to detect tumor-related molecules in the blood, the presence of which indicates a tumor at a very early stage, Sharq al-Awsat reported.
Scientists emphasize that it is hoped that the test can be applied to other types of cancer, saving millions of lives around the world.
